X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (91) 91
Publication (6) 6
Book Review (3) 3
Book / eBook (1) 1
Book Chapter (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (51) 51
index medicus (50) 50
female (43) 43
middle aged (38) 38
oncology (36) 36
aged (32) 32
adult (31) 31
male (30) 30
chemotherapy (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
aged, 80 and over (14) 14
cancer (13) 13
abridged index medicus (12) 12
breast neoplasms - drug therapy (11) 11
lung neoplasms - drug therapy (11) 11
fluorouracil - administration & dosage (10) 10
treatment outcome (10) 10
cisplatin - administration & dosage (9) 9
follow-up studies (9) 9
cisplatin (8) 8
drug therapy (8) 8
medicine, general & internal (8) 8
pilot projects (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
breast cancer (7) 7
carcinoma (7) 7
carcinoma, non-small-cell lung - drug therapy (7) 7
drug administration schedule (7) 7
lung cancer (7) 7
remission induction (7) 7
survival (7) 7
breast neoplasms - pathology (6) 6
care and treatment (6) 6
lung neoplasms - pathology (6) 6
neoplasm metastasis (6) 6
neoplasm staging (6) 6
radiotherapy (6) 6
survival analysis (6) 6
survival rate (6) 6
tamoxifen (6) 6
therapy (6) 6
5-fluorouracil (5) 5
article (5) 5
combined modality therapy (5) 5
cyclophosphamide - administration & dosage (5) 5
double-blind method (5) 5
doxorubicin - administration & dosage (5) 5
etoposide - administration & dosage (5) 5
paclitaxel (5) 5
prognosis (5) 5
radiosensitization (5) 5
research (5) 5
risk factors (5) 5
surveys and questionnaires (5) 5
time factors (5) 5
agriculture, multidisciplinary (4) 4
analgesics - therapeutic use (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic agents, phytogenic - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
breast neoplasms - mortality (4) 4
breast-cancer (4) 4
carcinoma, non-small-cell lung - pathology (4) 4
carcinoma, non-small-cell lung - radiotherapy (4) 4
drug evaluation (4) 4
hematology, oncology and palliative medicine (4) 4
infusions, intravenous (4) 4
liver neoplasms - secondary (4) 4
lung neoplasms - radiotherapy (4) 4
lungs (4) 4
methotrexate - administration & dosage (4) 4
neoplasms - complications (4) 4
non-small cell lung cancer (4) 4
non-small-cell lung cancer (4) 4
pain - drug therapy (4) 4
patients (4) 4
respiratory system (4) 4
statistics & probability (4) 4
tamoxifen - administration & dosage (4) 4
toxicity (4) 4
vincristine - administration & dosage (4) 4
women (4) 4
adenocarcinoma - drug therapy (3) 3
administration, oral (3) 3
adriamycin (3) 3
antineoplastic agents (3) 3
antineoplastic agents, phytogenic - adverse effects (3) 3
cancer pain (3) 3
carboplatin (3) 3
chemoprevention (3) 3
chemoradiation (3) 3
cisplatin - adverse effects (3) 3
colonic neoplasms - drug therapy (3) 3
combination chemotherapy (3) 3
docetaxel (3) 3
dosage and administration (3) 3
drug prescriptions - statistics & numerical data (3) 3
drug therapy, combination (3) 3
etoposide (3) 3
etoposide - adverse effects (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2007, 1, Translational medicine series, ISBN 9780849390210, Volume 3, viii, 265
Lung cancer is the leading cause of cancer-related deaths in the United States. Filling a gap in the literature, this resource translates recent laboratory... 
Chemotherapy | Treatment | drug therapy | Lungs | Antineoplastic Agents | Technological innovations | Lung Neoplasms | Molecular aspects | therapeutic use | Cancer | Oncology | Pulmonary Medicine | Lungs - Cancer - Molecular aspects
Book
Frontiers in Oncology, ISSN 2234-943X, 2013, Volume 3, pp. 219 - 219
Stage III non-small cell lung cancer (NSCLC) patients with poor performance status (PS) or co-morbidities are often not candidates for standard... 
Radiosensitization | Stage III non-small cell lung cancer | Cetuximab | EGFR | Performance status | cetuximab | stage III non-small cell lung cancer | performance status | radiosensitization
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 12/2017, Volume 123, Issue 23, pp. 4653 - 4662
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, & Physics, ISSN 0360-3016, 06/2008, Volume 71, Issue 2, pp. 407 - 413
Purpose: We report the toxicity profile and pharmacokinetic data of a schedule-dependent chemoradiation regimen using pulsed low-dose paclitaxel for... 
Journal Article
Journal Article
Journal Article